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Abstract   32	
 33	
Background:  Postprandial (PP) control remains a challenge for closed-loop (CL) systems. Few 34	
studies with inconsistent results have systematically investigated the PP period. 35	
Objective:  To compare a new CL algorithm with current pump therapy (OL) in the PP glucose 36	
control in type 1 diabetes (T1D) subjects. 37	
Methods: A crossover-randomized study was performed in two centers. 20 T1D subjects (F/M 38	
13/7, disease duration 22.6±9.9 years, A1c 7.8±0.7%) underwent an 8-hour mixed meal test on 39	
4 occasions. On two (CL1/CL2), after meal-announcement a bolus was given followed by an 40	
algorithm-driven basal infusion based on continuous glucose monitoring (CGM). Alternatively, 41	
in OL1/OL2 conventional pump therapy was used. Main Outcome Measures were: Glucose 42	
variability, estimated with the coefficient of variation (CV) of the area-under-the-curve (AUC) 43	
of plasma glucose (PG) and CGM values and from the analysis of the glucose-time series; 44	
mean, maximum (Cmax) and time to Cmax glucose concentrations and time in range (<70, 70-180, 45	
>180 mg/dl).  46	
Results: CVs of the glucose AUCs were low and similar in all studies (around 10%). However, 47	
CL achieved greater reproducibility and better PG control in the PP period: 48	
CL1=CL2<OL1<OL2 (PGmean 123±47 and 125±44 vs. 152±53 and 159±54mg/dl). Cmax OL 49	
217.1±67.0 vs. CL 183.3±63.9mg/dl, p<0.0001. Time-in-range was higher with CL vs. OL (80 50	
vs. 64%; p<0.001). Neither the time-below 70 mg/dl (CL 6.1 vs. OL 3.2%; p>0.05) nor the need 51	
for oral glucose were significantly different (CL 40.0% vs. OL 22.5% of meals; p=0.054).  52	
Conclusions: This novel CL algorithm effectively and consistently controls PP glucose 53	
excursions without increasing hypoglycemia.  54	
55	
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Introduction 56	
 57	
Postprandial (PP) glucose fluctuations are one of the main contributors to chronic 58	
hyperglycemia and glucose variability in subjects with type 1 diabetes (T1D). Additionally, the 59	
poor reproducibility of PP glucose response is burdensome not only for patients but also for 60	
healthcare professionals using and prescribing intensive insulin therapy. Automated closed loop 61	
(CL) glucose control systems are expected to improve PP hyperglycemia and variability. 62	
However, meal-induced glucose perturbations and PP hyperglycemia compensation strategies 63	
remain one of the most difficult challenges for CL systems in the management of T1D.  64	
Until now, different approaches have been suggested to counteract meal-induced disturbances in 65	
CL studies. Fully automated CL control without prior information regarding meal size and 66	
insulin delivery optimization have shown lower performance during the PP period either in 67	
single- or in dual-hormone CL systems (1-3). Other less-ambitious approaches in which meals 68	
are announced to the system (meal announcement, semi closed-loop) giving full prandial bolus 69	
(4,5), or at least a percentage (priming boluses), leaving the rest to the CL controller (6) have 70	
been evaluated. More recently, other strategies alternative to continuous subcutaneous insulin 71	
infusion (CSII) such as the addition of pramlintide, liraglutide or technosphere inhaled insulin 72	
have been shown to improve PP glucose excursions (7,8). However, these strategies do not 73	
relieve the burden of decision-making before meals and/or add complexity to the CL therapy. 74	
For these reasons, meal announcement appears to be the easiest way to improve PP glucose 75	
control in CL systems.  76	
Despite the use of meal announcement, the main challenge of control algorithms is to find a 77	
balance between PP glucose control and hypoglycemic risk, avoiding the overcorrection of 78	
hyperglycemia. An aggressive tuning for a lower PP glucose peak may cause insulin stacking 79	
producing late hypoglycemia. Several groups have incorporated safety strategies in their 80	
algorithms such as the inclusion of constraints on residual insulin activity (insulin on-board, 81	
IOB) (9), the addition of insulin feedback (10), or inclusion of glucagon as a counterregulatory 82	
control action (bi-hormonal CL control) (11,12), with some improvement during the PP period. 83	
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An alternative proposed strategy may be using sliding mode reference conditioning (SMRC). 84	
This is a safety loop, which needs to be added to the main control loop and is only active when 85	
IOB is going to overcome any previously defined constraint (13). However, to date only an in-86	
silico validation of this strategy is available. 87	
Recent at-home artificial pancreas (AP) studies have demonstrated improved daytime glucose 88	
control and less within-day and between days glycemic variability as compared to pump 89	
therapy. However, the reduction of glycemic variability was mainly due to a diminution in 90	
nocturnal glycemic variability (5,14). In addition, the PP period was not systematically 91	
addressed in these studies. Hence, the superiority of CL vs. open-loop (OL) during the PP 92	
period needs still to be proven.    93	
 94	
In this context, our study aimed to assess whether a SMRC-based CL controller is able to safely 95	
improve PP glycemic control in comparison with standard OL therapy based on CSII in subjects 96	
with type T1D. 97	
 98	
Research Design and Methods 99	
Study design and subjects 100	
This was a randomized, prospective, one-way, repeated measures (four periods, two sequences) 101	
crossover study in subjects with T1D under CSII. The protocol was approved by the Ethics 102	
Committees of the Clinic University Hospital of Valencia and the Clinic University Hospital of 103	
Barcelona (clinical settings).  The study was designed as an in-hospital approach fulfilling the 104	
regulatory conditions that applied in our country to this sort of projects before moving to at-105	
home settings. 106	
Subjects were eligible to participate if they were between 18 and 60 years of age, had a 107	
diagnosis of T1D for at least 1 year,   HbA1c between 6.0-8.5% and were on CSII for at least 6 108	
months. Hypoglycemia unawareness was ruled out using a validated questionnaire (15).  109	
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Each subject underwent an in-hospital 8-hour standardized mixed meal test (60g carbohydrate, 110	
CH) on 4 occasions. On 2 occasions (CL1 and CL2), after a meal-announcement an augmented 111	
bolus was given, followed by manual adjustments of the basal rate every 15 minutes according 112	
to a closed loop controller. On the other two occasions (OL1 and OL2) conventional CSII was 113	
used and boluses were based on the individual insulin/carbohydrates (I:CHO) ratios. All 114	
subjects were randomly assigned to sequence 1 (OL1-CL1-OL2-CL2) or 2 (CL1-OL1-CL2-115	
OL2) with a wash-out period of at least 1 week between studies.  116	
Patients were instructed to wear a continuous glucose monitor (CGM) device and follow a 117	
structured self-monitoring blood glucose (SMBG) protocol during a six-day period prior to the 118	
first meal test. Data from CGM and SMBG were used to obtain an individual estimated insulin 119	
sensitivity and a pharmacokinetic/pharmacodynamic model resulting in the calculation of the 120	
following parameters: I: CHO ratio, sensitivity factor, basal insulin needs, and insulin on board 121	
(IOB). These parameters were used to optimize the overall home blood glucose control (16,17) 122	
(OL) and also for the controller tuning (CL). 123	
 124	
Study devices 125	
CSII was carried out with the Paradigm Veo® insulin pump (Medtronic MiniMed, Northridge, 126	
CA) and CGM using Enlite-2 sensors® (Medtronic MiniMed, Northridge, CA). Two CGM 127	
were inserted at least 24h before the meal tests, to improve performance and avoid missing data 128	
and problems related to sensor drift. For safety and regulatory reasons two sensors were used in 129	
this phase of development to ensure the algorithm to be fed with the secondary CGM in case of 130	
sensor failure. In all subjects, calibration of CGM was performed using the Contour® Next Link 131	
(Ascensia Diabetes Care Holdings AG, Basel, Switzerland. Formerly Bayer). Glucose 132	
concentrations were also measured every 15 minutes with a reference method YSI 2300 Stat 133	
Plus Glucose Analyzer (YSI 2300, YSI Incorporated Life Sciences, Yellow Springs, Ohio, 134	
USA). 135	
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The CL system was based on a novel SMRC glucose controller (13) built in a PC. Glucose 136	
values from the two CGM devices were introduced manually every 15 minutes into the 137	
controller interface.  Manual operation greatly simplified regulatory approval of the system in 138	
the first submission of this type in Spain. However, this was not in detriment of unreasonably 139	
higher sampling periods. Remark for instance that the Florence system from Cambridge 140	
University, with extensive validation in inpatient and outpatient settings, uses 12 minutes as 141	
sampling period, compared to 15 minutes in our case [XX]  The system defined a primary and a 142	
secondary CGM device automatically, based on an accuracy analysis (Absolut Relative 143	
Difference –ARD– from reference) prior to the start of the CL controller. Only data from the 144	
primary CGM were used except in case of malfunction, resulting in automatic switch to the 145	
secondary CGM. Malfunction was defined as an ARD between the CGM reading and the PG 146	
reference greater than 40% at one time point or ARD greater than 30% in two consecutive 147	
periods. The insulin infusion rate for the next 15-minute time interval was calculated by the 148	
controller and manually set by the attending physician/nurse. 149	
The glucose controller consists in a feed-forward action plus two control loops: 150	
(a) The feed-forward action is an augmented bolus calculated based on meal announcement. The 151	
value of the bolus is the result of adding to the standard bolus the amount of basal insulin that 152	
would be delivered in the next hour in the case of being in open loop.  153	
(b) The inner control loop is a PID-type controller designed to drive the measured glucose to a 154	
target value. It is tuned from the insulin pump settings. 155	
(c) The outer control loop is based on SMRC and modulates the glucose target value on the 156	
estimated IOB minimizing the impact of controller over-correction resulting in late 157	
hypoglycemia. When the estimated IOB is beyond pre-specified limits a high-frequency 158	
discontinuous signal is generated and filtered inducing smooth changes in the target glucose 159	
value so that insulin-on-board constraints are not violated. Thus, this outer loop acts as a safety 160	
supervisory loop. The IOB estimation is calculated using a previous population pharmacokinetic 161	
model. Finally, the IOB limit is estimated individually based on one-week CGM monitoring 162	
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data and previous insulin pump settings. Compared to Insulin Feedback (IF), also used in 163	
combination to PID controllers [XX], SMRC is expected to induce an early pump shut-off due 164	
to the augmented bolus administration with a potential benefit in PP control, as compared to a 165	
later effect by IF driven by the estimated plasma insulin concentration. 166	
 167	
Mixed meal tests 168	
Before the meal test, fasting subjects were admitted to the clinical research units at 08:00 AM. 169	
In a sitting position, two venous lines were prepared, one for arterialized venous blood sampling 170	
(18) and the other for insulin/glucose infusion, if required. To ensure comparable metabolic 171	
conditions between studies, where appropriate, subjects received an intravenous infusion of 172	
regular human insulin in a feedback fashion, or glucose, to maintain plasma glucose at 90-100 173	
mg/dl until the beginning of the studies. At 12:00 h (t=0), a standard mixed meal (530 Kcal, 60g 174	
CHO, 45.3% CHO, 24.2% protein, 30.5% fat) was consumed in 15-20 minutes. At the same 175	
time, insulin was administered following the randomization protocol (OL or CL), and plasma 176	
glucose was monitored for the ensuing eight hours until the end of study at 20:00 h (time 480 177	
min). If plasma glucose fell below 70 mg/dl during two consecutive 15-min periods, oral 178	
glucose was administered in fixed amounts of 15g until recovery form hypoglycemia.  179	
 180	
Statistical analysis 181	
Mean glucose concentrations, time spent in different ranges (< 70, 70-180 and > 180 mg/dl), 182	
maximum (Cmax) and time to maximum (Tmax) of glucose values were used as a measure of 183	
glycemic control. Variability of the postprandial glycemic response was estimated from the 184	
coefficient of variation (CV) of the area under the curve (AUC) of PG and CGM values and 185	
from the analysis of the glucose-time series of the four studies (CL1, CL2, OL1, OL2).  186	
The primary study variable was the CV of PG during the whole PP period (CV_AUC-PG0-8h). 187	
However, the CV of glucose measurements was also calculated for the early (CV_AUC-PG0-3h) 188	
and the late (CV_AUC-PG3-8h) postprandial phases.  189	
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All of the above measures were also calculated from CGM values. 190	
The linear trapezoidal rule was used to calculate the AUC for glucose measurements for each 191	
study, obtaining two values for the CL (AUC_CL1 AUC_CL2) and two for the OL condition 192	
(AUC_OL1, AUC_OL2). Then CV was calculated as the ratio between the respective AUC’s 193	
SDs and means, so that CV_CL=  and CV_OL= . 194	
Cmax, Tmax and the time spent in range (70-180 mg/dl) were read directly from the concentration-195	
time data for each subject.  196	
As data were mostly not normally distributed, they were analyzed non-parametrically. The 197	
Wilcoxon signed rank-sum test was used to compare CVs of CL and OL studies. Glucose 198	
concentration time series, as well as all the other parameters, were analyzed using Kruskal-199	
Wallis One-Way ANOVA on Ranks. Post-hoc comparisons were carried out to examine the 200	
differences between pairs of groups after Kruskal-Wallis analysis: the Least Significant 201	
Difference (LSD) post hoc test was used to explore all possible pair-wise comparisons of means 202	
(OL1 vs. OL2, OL1 vs. CL1, OL1 vs. CL2, OL2 vs. CL1, OL2 vs. CL2, CL1 vs. CL2).  203	
Data analysis was carried out with SPSS software, version 20.0 (SPSS Inc., Chicago IL, USA). 204	
 205	
Sample size calculation.  206	
A power analysis was conducted. A one-sided t-test achieves 90% power to infer that the mean 207	
difference is not 0.000 when the total sample size of a cross-over design is 20, the actual mean 208	
difference is -4.813, the square root of the within mean square error is 5.000, and the 209	
significance level is 0.05. 210	
 211	
Results 212	
Twenty subjects with T1DM with fair glycemic control (13/7, females/males; age 40.7±10.4 213	
(mean±SD) years; BMI 25.7±3.0 kg/m2; diabetes duration 22.2±9.9 years; time on CSII 7.2±4.4 214	
years; HbA1c 7.8±0.7%) were recruited and all of them completed the study. 215	
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 216	
Efficacy - glycemic control 217	
Analysis of CV_AUCs did not show any improvement of glucose variability using CL as 218	
compared to OL, with values around 10% either with PG or CGM independently of the PP 219	
period phase (0-8h, 0-3h, 3-8h) (Table 1). However, analysis of glucose concentration time 220	
series was superior with a controller-driven insulin infusion. Indeed, PG was significantly lower 221	
in CL than in OL (OL1 152.4±53.4; OL2 159.3±53.8; CL1 123.3±46.9; CL2 124.9±44.3 mg/dl, 222	
p<0.0001), with no differences between CL studies (CL1-CL2 =-1.6 mg/dl with 95%CI [-6.9; 223	
3.8]). In contrast, mean PG during OL1 was significantly different from OL2 (-6.9 mg/dl [(-224	
12.3; -1.5]). The differences between OL and CL studies were also confirmed when CGM time 225	
series were analyzed (OL1 160.8±51.8; OL2 165.2±56.7; CL1 132.1±47.8; CL2 226	
127.1±42.3mg/dl, p<0.0001). However, in this case post-hoc analysis revealed no difference 227	
between OL (OL1-OL2 -4.4 mg/dl [-9.7; 1]) or between CL studies (CL1-CL2 -5 mg/dl [-0.4; 228	
10.4]). 229	
Time spent in range (70-180 mg/dl) calculated either in PG or CGM values, was significantly 230	
greater (80 vs. 64% PG; 78.8 vs. 60.5% CGM, p<0.05) in CL as compared to OL, without any 231	
significant difference in the time spent in hypoglycemia (6.1 vs. 3.2% PG; 5.2 vs. 1.9% CGM, 232	
p<0.05) (Table 2). Additionally, Cmax was significantly lower in CL studies either considering 233	
PG (OL 217.1±67.0 vs. CL 183.3±63.9, p=0.00029) or CGM data (OL 227.4±66.7 vs. CL 234	
196.2±59.4, p<0.0001), without any difference between CL (CL1=CL2) or OL (OL1=OL2) 235	
studies (p=NS for post-hoc analysis).  236	
 237	
Safety – hypoglycemic episodes 238	
The mean amount of oral glucose given to recover from mild hypoglycemic episodes did not 239	
differ between studies (OL 7.2±83.3g vs. CL 12.8±114.2g, p=0.121). Although numerically 240	
greater, the percentage of studies in which oral glucose was needed (40% vs 22.5%), as well as 241	
the mean number of rescues (0.825±1.20 vs 0.5±1.18, p=0.054) was not significantly different 242	
	 11	
in CL as compared to OL studies. A shift from primary to secondary CGM was infrequent and 243	
also there was no need to feed the CL using reference data. 244	
 245	
Insulin dose 246	
The mean total insulin dose (OL 0.198±0.933 vs. CL 0.209±0.987, U/kg; p<0.0001) and the 247	
mean basal insulin dose (OL 0.089±0.049 vs. CL 0.097±0.106, CL2 0.093±0.098 U/kg; 248	
p<0.0001) were significantly greater in CL as compared to OL studies (Figure 2). However, the 249	
mean global difference in daily doses was numerically small with a size effect of 2.2%. The 250	
overall ratio of basal to prandial insulin during the experiments was 44.6/55.4 % in OL vs. 251	
45.3/54.7% in CL studies.  252	
 253	
Conclusions 254	
Our study shows that the novel SMRC-based CL algorithm improved glucose control 255	
consistently and safely across the early and late postprandial phase without increasing 256	
hypoglycemia risk. Glucose variability was relatively small in both study arms and was not 257	
improved in CL as compared to standard treatment. 258	
Improvement of PP hyperglycemia avoiding late hypoglycemia is one of the main challenges of 259	
all the groups involved in AP research.  Intra-patient variability, errors in glucose sensor 260	
measurements, and, mainly, the delay in the control action are some of the limiting barriers. 261	
However, to our knowledge, studies comparing OL vs. CL more than once and only during the 262	
PP period in controlled conditions are very scarce.  263	
Many hybrid blood glucose control systems include a feed-forward action as a full standard 264	
bolus or a portion of the bolus for safety reasons. To reduce postprandial peaks induced by large 265	
meals or foods with a large glycemic index, Walsh et al. (19) proposed the delivery of a 266	
“superbolus”, increasing the standard bolus and then reducing the basal insulin rate over a 267	
period of time. However, direct demonstration of the effectiveness of this approach has not been 268	
provided in the OL or in the CL setting.  269	
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An OL approximation to the superbolus is the so-called iBolus, a methodology for CGM-based 270	
calculation of the prandial insulin dose, which results on most occasions in a greater-than-usual 271	
bolus followed by a transient reduction of basal infusion. The iBolus was validated in a previous 272	
study (20) showing that the use of an OL “superbolus” is feasible and efficient when combined 273	
with a proper subsequent decrease of the basal insulin controlling small meals (40 g CHO).  274	
Chase et al. (21) showed that adding 30% to insulin bolus calculated by I:CH ratio was the best 275	
option to control PP glycemic excursion in comparison to either a standard bolus or a bolus 15 276	
minutes before the meal in CL studies. Nevertheless, postprandial hyperglycemic excursions in 277	
that study were much higher than in our study (glucose peak 220 vs 183 mg/dl, respectively). A 278	
different approach,  focused on the reduction of the incidence of postprandial hypoglycemia, 279	
was adopted by Elleri et al. (22). They compared CL therapy with a 25% reduction of prandial 280	
boluses against standard prandial insulin boluses. However, hypoglycemia was very rare in both 281	
groups and no demonstration of greater safety was found.  282	
Regarding our SMRC-based algorithm, it was previously evaluated in a cohort of ten adult 283	
virtual patients in a 16-h protocol (8:00 to 24:00 h), including three meals in 10 days. With this 284	
algorithm, potentially severe hypoglycemic events (< 50 mg/dl) were almost inexistent, the 285	
percentage of time < 70 mg/dl was reduced more than a half and there was not an increase in 286	
time > 180 mg/dl (13). Certainly, our study was intended to translate these in silico results into a 287	
clinical study protocol. The protocol was designed to evaluate the performance of a new CL 288	
algorithm in improving postprandial glycemic control (time spent in desired ranges) and intra-289	
subject glucose variability. In our study, an augmented prandial bolus was given in the context 290	
of a SMRC CL system that limits insulin delivery when IOB is unacceptably high 291	
independently of glycemic value. As a consequence, delivery of a “superbolus” was 292	
immediately translated into a basal infusion shut-off, due to the glucose target modulation 293	
triggered by the violation of the IOB limit by the bolus. Basal infusion was then restored driven 294	
by the PID controller once IOB returned to values below limit. The main advantage of our CL 295	
system was that it significantly reduced both early and late postprandial hyperglycemia 296	
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exposure (>50% reduction in time spent >180 mg/dl) without a significant increased risk of 297	
hypoglycemia.  298	
The critical point in the SMRC controller is the adjustment of the IOB limit.  Too high values 299	
may cause the outer loop being inactive and ineffective reducing the risk of hypoglycemia. On 300	
the other side, too small values can make the internal control loop irrelevant. A general tuning 301	
of the IOB limit will lead to different values according to different situations: postprandial state, 302	
exercise, night control, etc. We would like to emphasize that due to its nature the algorithm for 303	
CL control based SMRC may be combined to main CL controllers of any nature, offering thus a 304	
generalized safety system to avoid overcorrection problems, including PP glucose control. An 305	
additional advantage of this approach is that the SMRC loop does not affect the structure of the 306	
inner controller, which could be designed independently. Finally, the SMRC loop may allow 307	
also a more aggressive tuning of the inner controller if necessary.  308	
Glycemic variability was another objective of our study. From our results, our CL algorithm did 309	
not improve glucose variability. However, the analysis of temporal series showed that 310	
differences on PG values between the repeated CL studies were lower than those observed in 311	
the OL experiments, suggesting a higher reproducibility of CL results. Importantly, the efficacy 312	
of CL controllers against glucose variability has not been specifically evaluated in previous 313	
studies. For instance, the 48-hour duration out-patient study published by Van Bon et al. 314	
included repeated meals, but they were not controlled regarding the composition and pre-315	
prandial conditions, making comparisons with our study difficult (2). Some recently long-term 316	
free-living studies have evaluated daytime glycemic variability. Although the PP periods were 317	
not systematically investigated in Thabit et al (5), this study showed a reduction of inter-day 318	
daytime variability expressed as CV from 19% with OL to 16% with CL in the adult cohort. It 319	
should be noticed that variability in that study was nearly twice greater as compared with our 320	
study, probably due to the highly controlled conditions of our study, which make any 321	
improvement of PP variability very difficult. 322	
	 14	
The use of our CL controller was associated with a clinically marginal increase in the total 323	
insulin dose (average 0.015 U/kg body weight). This finding is not enough to explain the 324	
beneficial effect observed on PP glucose excursions with CL, indicating indirectly that not only 325	
the total insulin dose but also how insulin infusion was implemented contribute to glucose 326	
control.  327	
We are aware that our study has some limitations. It was designed and performed in a clinical 328	
research in-patient environment including a manually implemented controller action in a 329	
currently context of fully automatic control at-home studies. However, our new CL controller 330	
needed to fulfill regulatory conditions before moving to an outpatient scenario. We used a single 331	
meal with a specific composition, which was given in a specific timeframe of the day. This 332	
limits extrapolation of results to other meal composition and daily life conditions.  333	
In summary, our CL algorithm is able to effectively, consistently and safely control the PP 334	
glycemic excursions diminishing hyperglycemia in the post absorptive state without a clinically 335	
meaningful increasing risk of hypoglycemia. Future studies including those in transitional 336	
settings and also at-home are necessary to further validate our results in free daily life 337	
conditions. 338	
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